Opioid Abuse Deterrence: FDA Development Ideas Are Out Of This World
Executive Summary
To stimulate new ideas for better formulations, outgoing FDA commissioner Hamburg consulted X Prize Foundation about innovation competition.
You may also be interested in...
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.